Virus reduction in an intravenous immunoglobulin by solvent/detergent treatment, ion-exchange chromatography and terminal low pH incubation

Burnouf, 2000, Reducing the risk of infection from plasma products: specific preventative strategies, Blood Rev, 14, 94, 10.1054/blre.2000.0129 Kempf, 2007, Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins, Biologicals, 35, 35, 10.1016/j.biologicals.2006.01.002 Yap, 1997, Viral safety of IvIg, 67 Chidwick, 1999, Clinical experience with a new solvent detergent-treated intravenous immunoglobulin free of hypotensive effects, Vox Sang, 77, 204, 10.1046/j.1423-0410.1999.7740204.x Burnouf, 1993, Chromatograpic removal of viruses from plasma derivatives, Dev Biol Stand, 81, 199 Kistler, 1962, Large scale production of human plasma fractions. Eight years experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier, Vox Sang, 7, 414, 10.1111/j.1423-0410.1962.tb03274.x Cohn, 1946, Preparation and properties of serum and plasma proteins IV A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids, J Am Chem Soc, 68, 459, 10.1021/ja01207a034 Oncley, 1949, The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and B1-lipoprotein into subfractions of human plasma, J Am Chem Soc, 71, 541, 10.1021/ja01170a048 Committee for Proprietary Medicinal Products for Human Use. European medicines agency: guideline on plasma-derived medicinal products. EMA/CPMP/BWP/706271/2010. Horowitz, 1993, Viral safety of solvent-detergent treated blood products, Dev Biol Stand, 81, 147 Seitz, 2002, Comparable virus inactivation by bovine or vegetable derived tween 80 during solvent/detergent treatment, Biologicals, 30, 197, 10.1006/biol.2002.0328 Horowitz, 1985, Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri (n-butyl) phosphate detergent combinations, Transfusion, 25, 16, 10.1046/j.1537-2995.1985.25686071422.x Soluk, 2008, Pathogen safety of intravenous Rh immunoglobulin liquid and other immune globulin products: enhanced nanofiltration and manufacturing process overview, Am J Ther, 15, 435, 10.1097/MJT.0b013e318160c1b7 Trejo, 2003, Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process, Vox Sang, 84, 176, 10.1046/j.1423-0410.2003.00279.x Cameron, 1997, The removal of model viruses, poliovirus type 1 and canine parvovirus, during the purification of human albumin using ion-exchange chromatographic procedures, Biologicals, 25, 391, 10.1006/biol.1997.0115 Adcock, 1998, Chromatographic removal and heat inactivation of hepatitis A virus during manufacture of human albuman, Biotechnol Appl Biochem, 28, 85 Strauss, 2009, Anion exchange chromatography provides a robust, predictable process to ensure viral safety of biotechnology products, Biotechnol Bioeng, 102, 168, 10.1002/bit.22051 Roberts, 2007, Virus inactivation by protein denaturants used in affinity chromatography, Biologicals, 35, 343, 10.1016/j.biologicals.2007.02.005 Healthcare, 2009, Use of sodium hydroxide for cleaning and sanitising chromatography media and systems, Appl Note, 18, 1124 Boschetti, 2003, Stability of minute virus of mice against temperature and sodium hydroxide, Biologicals, 31, 181, 10.1016/S1045-1056(03)00037-X Farcet, 2010, Hepatitis A virus antibodies in immunoglobulin preparations, J Allergy Clin Immunol, 125, 198, 10.1016/j.jaci.2009.09.008 Lemon, 1985, Incomplete neutralization of hepatitis A virus in vitro due to lipid-associated virions, J Gen Virol, 66, 2501, 10.1099/0022-1317-66-11-2501 Dichtelmuller, 2011, Contribution to safety of immunoglobulin and albumin from virus partitioning and inactivation by cold ethanol fractionation: a data collection from plasma protein therapeutics association member companies, Transfusion, 51, 1412, 10.1111/j.1537-2995.2010.03003.x European Medicines Agency. Quality risk management (ICH Q9) EMA/INS/GMP/79766/2011. Moy, 2010, Efficacy and safety of a new immunoglobulin G product, Gammaplex®, in primary immunodeficiency disease, Clin Exp Immunol, 162, 510, 10.1111/j.1365-2249.2010.04247.x Poelsler, 2008, A new liquid immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity, Vox Sang, 94, 184, 10.1111/j.1423-0410.2007.01016.x